TAM
SLN

TFG Asset Management’s Silence Therapeutics SLN Stock Holding History

TFG Asset Management’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.32M Buy
630,161
+264,792
+72% +$1.46M 0.64% 26
2025
Q4 		$2.22M Buy
+365,369
New +$2.34M 0.47% 25

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

TFG Asset Management's SLN Position: Q1 2026 in Review

TFG Asset Management increased its Silence Therapeutics (SLN) stake by 72% in Q1 2026, buying an estimated $1.46M and bringing the position to 630,161 shares worth $3.32M. The position accounts for 0.64% of the portfolio, ranked #26.

TFG Asset Management first reported a position in SLN in Q4 2025 and has held it in 2 quarters since. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

  • TFG Asset Management held 630,161 shares of Silence Therapeutics worth $3.32M as of Q1 2026.
  • TFG Asset Management bought 264,792 Silence Therapeutics shares in Q1 2026, an estimated $1.46M.
  • Silence Therapeutics made up 0.64% of TFG Asset Management's portfolio in Q1 2026, its #26 holding.
  • TFG Asset Management first reported a position in Silence Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on TFG Asset Management's 13F filing for Q1 2026, filed 15 May 2026.